Instil Bio, Inc. reported its third quarter 2024 financial results and provided a corporate update, highlighting its new strategic direction. The company confirmed the recent in-licensing of SYN-2510, a PD-L1xVEGF bispecific antibody, for global development and commercialization outside of China. This asset is now positioned as a potential best-in-class therapy.
The company anticipates a clinical data update for SYN-2510/IMM2510 from ImmuneOnco in China during the first half of 2025. Furthermore, the initiation of a Phase 1b/2 combination trial with chemotherapy in first-line non-small cell lung cancer (NSCLC) is expected in late 2024, and in triple-negative breast cancer (TNBC) in the first half of 2025, both by ImmuneOnco in China.
Instil Bio also plans to initiate a U.S. clinical study of SYN-2510/IMM2510 in NSCLC during the second half of 2025. These timelines underscore the company's commitment to rapidly advancing its new lead candidate through clinical development in key oncology indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.